The study of predictive factors for the effect of Salmeterol/Fluticasone combination(SFC) on the patients with obstructive pulmonary dysfunction.

The study of predictive factors for the effect of Salmeterol/Fluticasone combination(SFC) on the patients with obstructive pulmonary dysfunction. - Evaluation of Salmeterol/ Fluticasone propionate compound effecacy in chronic obstructive pulmonary disease.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010276

Enrollment

Registered

2013-03-19

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obstructive pulmonary dysfunction

Interventions

salmeterol/fulticasone propionate combination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) FEV1/FVC< 70% pre-bronchodilator 2) Age 40-75 y.o. 3) possible observe for 4wks 4) consent in writing

Exclusion criteria

Exclusion criteria: 1) medication of corticosteroid in 4wks 2) medication of anticholinergic drug in 4wks 3) medication of long acting beta agonist in 4 wks 4) inhalation of short acting beta agonist in 6hrs 5) patients who has heart failure, severe arrhythmia. 6) medication of beta blocker 7) active infectious disease and tuberculous disease 8) pationts who had resected lung 9) psycosomatic patients 10) allergy for SFC 11) difficult to do spirometry 12) pregnancy 13) diagnosis for other pulmonary disease

Design outcomes

Primary

Measure	Time frame
FEV1	—

Countries

Japan

Contacts

Public ContactKentaro MACHIDA

Kagoshima university pulmonary medicine

machida@m.kufm.kagoshima-u.ac.jp0992756481

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026